Onc.AI

Onc.AI is a privately held digital health company dedicated to radically improving oncology decision-making. The company leverages a market-leading oncology real-world dataset that includes diagnostic imaging, electronic medical records (EMR), labs, and genomics. Onc.AI is developing a pipeline of AI models to fulfill the potential of precision oncology, with its first product designed to assist medical oncologists in making treatment decisions for metastatic lung cancer patients treated with PD-1 immunotherapy.

Onc.AI raised $25 million in Series A financing in January 2023 and $6 million in Series Seed financing in November 2020. The company has presented its research at several prestigious conferences, including the American Society of Clinical Oncology (ASCO) in June 2023, the American Association for Cancer Research (AACR) in April 2023, the American Medical Informatics Association (AMIA) 2023 AI Evaluation Showcase in May 2023, and the Society for Immunotherapy of Cancer (SITC) in October 2022.

Onc.AI has offices in the San Francisco Bay Area, United States, and Waterloo, Ontario, Canada, and supports remote work. The company offers comprehensive healthcare, dental, and vision plans for both US-based and Canadian employees, provides unlimited paid time off (PTO), and celebrates both American and Canadian Thanksgiving. Additionally, Onc.AI hosts company-sponsored events, including virtual and in-person regional events.